scholarly article | Q13442814 |
P50 | author | Jan Holmgren | Q5811529 |
Mohammad Ali | Q54268652 | ||
John Clemens | Q58987399 | ||
Mahesh C Puri | Q59820848 | ||
Anna Lena Lopez | Q73587266 | ||
Jacqueline L Deen | Q87896207 | ||
Allan Harding | Q110221149 | ||
Nirmal K. Ganguly | Q111307211 | ||
Dipika Sur | Q114445759 | ||
Suman Kanungo | Q114445760 | ||
Deok Ryun Kim | Q116774170 | ||
Binod Sah | Q116793834 | ||
Allison M Paisley | Q116793835 | ||
Banwarilal Sarkar | Q116793836 | ||
Rodney Carbis | Q116793837 | ||
Raman Rao | Q116793838 | ||
Stephen Attridge | Q116793839 | ||
P2093 | author name string | G Balakrish Nair | |
Sujit K Bhattacharya | |||
Seung Hyun Han | |||
Jin Kyung Park | |||
Byomkesh Manna | |||
Thu Van Nguyen | |||
Swapan K Niyogi | |||
P2860 | cites work | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design | Q24569560 |
Cholera vaccines for the developing world. | Q37138956 | ||
Cholera outbreaks caused by an altered Vibrio cholerae O1 El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007 to 2008. | Q37191671 | ||
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam | Q39439547 | ||
Cholera in Mozambique, variant of Vibrio cholerae | Q42541007 | ||
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial | Q44235991 | ||
Field trial of oral cholera vaccines in Bangladesh | Q46726270 | ||
Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial | Q57926913 | ||
El Tor cholera with severe disease: a new threat to Asia and beyond | Q57936162 | ||
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up | Q57936163 | ||
Cholera vaccines: WHO position paper | Q83941810 | ||
P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cholera vaccine | Q1812946 |
cholera | Q12090 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | e1289 | |
P577 | publication date | 2011-10-18 | |
P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
P1476 | title | Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial | |
P478 | volume | 5 |
Q53311743 | 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. |
Q34484003 | A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mic |
Q35645943 | An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India |
Q24620207 | Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera |
Q40545451 | Assessing different measures of population-level vaccine protection using a case-control study. |
Q92264656 | Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine |
Q47794110 | Causes of impaired oral vaccine efficacy in developing countries. |
Q38370138 | Cholera - management and prevention. |
Q37588131 | Cholera transmission dynamic models for public health practitioners |
Q37225765 | Cholera vaccination in urban Haiti |
Q41997569 | Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design |
Q51732904 | Considerations around the introduction of a cholera vaccine in Bangladesh. |
Q47602346 | Cost Evaluation of a Government-Conducted Oral Cholera Vaccination Campaign-Haiti, 2013. |
Q34305452 | Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar |
Q40217031 | Coverage and acceptability of cholera vaccine among high-risk population of urban Dhaka, Bangladesh |
Q40145989 | Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh |
Q26823170 | Critical analysis of compositions and protective efficacies of oral killed cholera vaccines |
Q92264663 | Current and future cholera vaccines |
Q47095750 | Delivery cost analysis of a reactive mass cholera vaccination campaign: a case study of Shanchol™ vaccine use in Lake Chilwa, Malawi |
Q37643320 | Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. |
Q37225767 | Development of a cholera vaccination policy on the Island of Hispaniola, 2010-2013 |
Q36869585 | Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up |
Q35261144 | Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis |
Q38978824 | Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh |
Q34403586 | Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide |
Q40295575 | Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial |
Q34994131 | Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea |
Q57927158 | Feasibility, coverage and cost of oral cholera vaccination conducted by icddr,b using the existing national immunization service delivery mechanism in rural setting Keraniganj, Bangladesh |
Q40088781 | Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. |
Q64123267 | IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity |
Q37360102 | Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan |
Q38059916 | Immune responses and protection in children in developing countries induced by oral vaccines |
Q33588522 | Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera |
Q36044030 | Immune responses to cholera in children |
Q34334260 | Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh |
Q37340450 | Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length |
Q47410855 | Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis |
Q33552968 | Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti |
Q64240401 | Impact of a Large-Scale Handwashing Intervention on Reported Respiratory Illness: Findings from a Cluster-Randomized Controlled Trial |
Q47810215 | Impact of adding hand-washing and water disinfection promotion to oral cholera vaccination on diarrhoea-associated hospitalization in Dhaka, Bangladesh: evidence from a cluster randomized control trial |
Q35963349 | Impact of oral cholera vaccines in cholera-endemic countries: A mathematical modeling study |
Q30151668 | Improving immunization approaches to cholera |
Q36654953 | Incidence of severe diarrhoea due to Vibrio cholerae in the catchment area of six surveillance hospitals in Bangladesh. |
Q92339950 | Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh |
Q41426133 | Insights from natural infection-derived immunity to cholera instruct vaccine efforts |
Q45242442 | Introducing cholera vaccination in Asia, Africa and Haiti: a meeting report |
Q35744920 | Is a Cholera Outbreak Preventable in Post-earthquake Nepal? |
Q50054542 | Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate |
Q34087755 | Killed oral cholera vaccines: history, development and implementation challenges |
Q92296556 | Mapping cholera outbreaks and antibiotic resistant Vibrio cholerae in India: An assessment of existing data and a scoping review of the literature |
Q33578033 | Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines |
Q35940653 | Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh |
Q35091566 | Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions |
Q37225744 | Modeling the effect of water, sanitation, and hygiene and oral cholera vaccine implementation in Haiti |
Q37953796 | New-generation vaccines against cholera |
Q36881533 | O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh |
Q38078460 | Old foes, new challenges: syphilis, cholera and TB. |
Q36187863 | Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings |
Q40440951 | Optimized oral cholera vaccine distribution strategies to minimize disease incidence: A mixed integer programming model and analysis of a Bangladesh scenario |
Q64130108 | Organization and implementation of an oral cholera vaccination campaign in an endemic urban setting in Dhaka, Bangladesh |
Q51150718 | PaxVax CVD 103-HgR single-dose live oral cholera vaccine. |
Q40189342 | Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh |
Q34456242 | Post-licensure deployment of oral cholera vaccines: a systematic review |
Q92574357 | Preventing cholera in India: Synthesizing evidences through a systematic review for policy discussion on the use of oral cholera vaccine |
Q51784737 | Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects. |
Q39448785 | Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis |
Q21090119 | Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks |
Q36153627 | Retrospective Analysis of Serotype Switching of Vibrio cholerae O1 in a Cholera Endemic Region Shows It Is a Non-random Process |
Q64951541 | Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India. |
Q48344793 | Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines. |
Q64054143 | Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial |
Q34359766 | Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy |
Q37992392 | Safety reporting in developing country vaccine clinical trials-a systematic review |
Q36593379 | Socio-cultural determinants of anticipated acceptance of an oral cholera vaccine in Western Kenya |
Q35892956 | Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach |
Q57481187 | The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships |
Q35867213 | Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice |
Q37130173 | Trials and tribulations of conducting interventional studies in urban slums of a developing country: Experiences from Kolkata, India |
Q34474623 | Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea bissau |
Q28080866 | Vaccines against enteric infections for the developing world |
Q26995690 | Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus |
Q27004488 | Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae |
Q33572955 | Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India |
Search more.